Gilead Sciences, Inc. (LON:0QYQ)

Market Cap	111.84B
Revenue (ttm)	21.64B
Net Income (ttm)	6.03B
Shares Out	n/a
EPS (ttm)	4.78
PE Ratio	18.54
Forward PE	14.43
Dividend	2.38 (1.98%)
Ex-Dividend Date	Sep 15, 2025

Volume	11,093
Average Volume	14,525
Open	120.00
Previous Close	119.60
Day's Range	119.41 - 122.85
52-Week Range	87.86 - 130.00
Beta	0.33
RSI	44.41
Earnings Date	Feb 10, 2026

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 17,600
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QYQ

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD